Abstract
ObjectivesTo compare the surgical, pathological and oncological outcomes of single-port access (SPA) laparoscopy against laparotomy for large ovarian tumor (>15 cm) suspected to be a borderline ovarian tumor (BOT) on preoperative imaging.MethodsA retrospective review of the patients who underwent SPA laparoscopy (SPA Group) or laparotomy (Laparotomy Group) for suspected BOT was performed. Surgical outcomes, including the rates of iatrogenic spillage of tumor contents, and oncological outcomes, such as recurrence-free survival (RFS) and overall survival (OS), were compared between the two groups. Correlation between intraoperative frozen section analysis and permanent pathology results was also assessed.ResultsA total of 178 patients underwent surgical treatment for suspected large BOT. Among them, 105 patients with a mean tumor diameter of 20.9 ± 6.5 cm underwent SPA laparoscopy, and the other 73 patients, with a mean tumor diameter 20.2 ± 5.9 cm, underwent laparotomy. The mean operation time did not differ between the two groups (99.1 ± 41.9 min for SPA Group vs. 107.3 ± 35.7 min for Laparotomy Group, p = 0.085). There was no difference in the occurrence of iatrogenic spillage of tumor contents between the groups either (11.4% in the SPA Group vs. 6.8% in the Laparotomy Group, p = 0.381). However, the postoperative complication rates were significantly higher in the Laparotomy Group compared with SPA Group (16.4% vs. 5.7%, p = 0.025). The surgical approach was not associated with the misdiagnosis rates of frozen section analysis (19% in the SPA Group vs. 26% in the Laparotomy Group, p = 0.484). The most common histologic type of the tumors was mucinous in both groups.ConclusionSPA laparoscopy is feasible, safe, and not inferior to laparotomy for surgical treatment of large ovarian tumors that suspected to be BOT on preoperative imaging.
Highlights
A borderline ovarian tumor (BOT), characterized as a tumor with a low potential for malignancy, accounts for approximately 10 to 15% of all epithelial ovarian tumors [1,2,3]
The mean operation time did not differ between the two groups (99.1 ± 41.9 min for Single-Port Access (SPA) Group vs. 107.3 ± 35.7 min for Laparotomy Group, p = 0.085)
The surgical approach was not associated with the misdiagnosis rates of frozen section analysis (19% in the SPA Group vs. 26% in the Laparotomy Group, p = 0.484)
Summary
A borderline ovarian tumor (BOT), characterized as a tumor with a low potential for malignancy, accounts for approximately 10 to 15% of all epithelial ovarian tumors [1,2,3]. It has distinguishing clinical features that are intermediate between benign ovarian tumors and invasive ovarian cancer. BOT can manifest as a metastatic disease and can recur, similar to malignant ovarian cancer, it generally behaves benignly and is usually diagnosed at an early stage and a younger age. For these reasons, it has excellent prognosis compared to malignant ovarian cancer [4]. The current standard treatment for BOT is complete staging, including hysterectomy, bilateral salpingo-oophorectomy (BSO), omentectomy, cytology analysis, and resection of all suspicious tissues, similar to surgery for malignant tumors [5]. Conservative surgery is acceptable in premenopausal women who want to preserve fertility due to its favorable prognosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.